It's hip to be Square right now. Or is it? How do we assess whether it -- and other recent IPOs -- went well, not just for investors but overall? In this episode of the a16z Podcast, Nicole Irvin and Stephen McDermid from our startup corp dev team -- and Andreessen Horowitz managing partner Scott Kupor -- share an internal "hallway conversation" of sorts around how to make sense of market reactions to recent IPOs, and more broadly, how to compare private vs. public valuations (and investors). Is there a method to the madness, a formula to compare these from beginning to end? Does it make a difference if you're creating a new category (like SaaS previously) or are in an existing one? Finally, we share views on the somewhat religious debate about whether public is really the new private, growth vs. profitability, and more. Especially as startups are always optimizing for so many competing things at any given time.

There are those who would say that Aubrey de Grey is out to cure death, but what this former artificial intelligence specialist turned gerontologist is really focused on is health -- and the side effect of health is living a lot longer. In this segment of the a16z podcast we talk with Aubrey de Grey on the subject of aging and health, and how his training as a computer scientist helped him approach the problem in a different way from traditional biologists. The intersection of software and biology, and how this “troublemaker” from the computer science world is trying to keep us all healthy for a very, very long time.